Italia markets open in 5 hours 18 minutes

Imunon, Inc. (0HUZ.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,4616-0,0785 (-5,10%)
Alla chiusura: 04:19PM GMT
Schermo intero
Chiusura precedente1,5401
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume6.400
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)2,09
Rapporto PE (ttm)N/D
EPS (ttm)-3,9680
Prossima data utili14 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    IMUNON Announces Strategic Investment in Transomic Technologies

    Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive Chairman to join Transomic’s Board of Directors LAWRENCEVILLE, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced a $375,000 investment in Transomic Technologies, a private company offering a comprehensive arra

  • GlobeNewswire

    Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses

    Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it has received $1.4 million in net cash proceeds from the sale of approximately $1.5 million of its unused New Jerse

  • GlobeNewswire

    Celsion Corporation Announces Stock Consolidation

    LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of its outstanding Common Shares on the basis of one (1) new Common Share for every fifteen (15) currently outstanding Common Shares. The new Common Shares will be effective for trading